These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17045223)

  • 1. Animal models of obesity-associated chronic kidney disease.
    Mak RH; Kuo HJ; Cheung WW
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):374-85. PubMed ID: 17045223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of diabetes mellitus.
    Rees DA; Alcolado JC
    Diabet Med; 2005 Apr; 22(4):359-70. PubMed ID: 15787657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity, diabetes, adiponectin and the kidney: a podocyte affair.
    Zoccali C; Mallamaci F
    Nephrol Dial Transplant; 2008 Dec; 23(12):3767-70. PubMed ID: 18802210
    [No Abstract]   [Full Text] [Related]  

  • 5. The contribution of animal models to the study of obesity.
    Speakman J; Hambly C; Mitchell S; Król E
    Lab Anim; 2008 Oct; 42(4):413-32. PubMed ID: 18782824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, insulin resistance and kidney disease risk: insights into the relationship.
    Sarafidis PA
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):450-6. PubMed ID: 18695384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rodent models of streptozotocin-induced diabetic nephropathy.
    Tesch GH; Allen TJ
    Nephrology (Carlton); 2007 Jun; 12(3):261-6. PubMed ID: 17498121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and application of rodent models for type 2 diabetes.
    Chen D; Wang MW
    Diabetes Obes Metab; 2005 Jul; 7(4):307-17. PubMed ID: 15955116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and kidney disease: a big dilemma.
    Kramer H; Luke A
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):237-41. PubMed ID: 17420667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting exercise regimens and strains to modify obesity and diabetes in rodents: an overview.
    Ghosh S; Golbidi S; Werner I; Verchere BC; Laher I
    Clin Sci (Lond); 2010 Apr; 119(2):57-74. PubMed ID: 20402668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of animal models in the study of diabetes mellitus.
    Chatzigeorgiou A; Halapas A; Kalafatakis K; Kamper E
    In Vivo; 2009; 23(2):245-58. PubMed ID: 19414410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess weight as a risk factor for kidney failure.
    Nguyen S; Hsu CY
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):71-6. PubMed ID: 17293680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease.
    Wahba IM; Mak RH
    Clin J Am Soc Nephrol; 2007 May; 2(3):550-62. PubMed ID: 17699463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversal of renal fibrosis: lessons from experimental models].
    Dussaule JC; Chatziantoniou C
    Bull Acad Natl Med; 2008 May; 192(5):987-1000; discussion 1000-1. PubMed ID: 19238788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between chronic kidney disease prevalence and end-stage renal disease risk.
    Hallan SI; Vikse BE
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):286-91. PubMed ID: 18408480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats.
    Zhang X; Jia Y; Jackson EK; Tofovic SP
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):56-63. PubMed ID: 17261964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
    Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.